You are currently browsing the tag archive for the ‘pharma’ tag.
Konstantin Hondros & Milena Leybold
Just over a year ago, Milena Leybold and Leonhard Dobusch asked, Why is there no open-source vaccine against Covid-19? and discussed arguments why open-source vaccines are difficult to achieve. In March 2022, The Financial Times published an article by Donato Paolo Mancini, Jamie Smyth, and Joseph Cotterill asking Will ‘open-source’ vaccines narrow the inequality gap exposed by Covid? (behind a subscription barrier) and indicating that the landscape of open-source vaccines may have changed substantially.This blog post is thought of as a reply and extension to this very informative report that introduces mainly two organizations producing or aiming to produce open-source vaccines: Afrigen Biologics and Vaccines (Afrigen) and the Texas Children’s Hospital Center for Vaccine Development (CVD with their vaccine Corbevax). For sure, Afrigen and CVD approach vaccine development, production, and distribution much more openly than most of the vaccines dominating the market. Still, it is unclear to what extent they should be considered as “open-source.” To clarify this topic, we scrutinize what an open-source vaccine ideally could be, to what degree Afrigen or CVD fit the ideals of open-source, and what other attempts for open-source vaccine alternatives are currently under development.
Read the rest of this entry »
We, that is Sigrid Quack, Konstantin Hondros, Katharina Zangerle and I, proudly present the article “Between Anxiety and Hope? How Actors Experience Regulatory Uncertainty in Creative Processes in Music and Pharmy”, which has recently been published in “Research in the Sociology of Organizations” (RSO) as part of a volume on “Organizing Creativity in the Innovation Journey”. Check out the abstract below:
Uncertainty about Intellectual Property Regulations (IPR) is prevalent in today’s knowledge-based and creative industries. While prior literature indicates that regulatory uncertainty affects creative processes, studies that systematically analyze the effects of IPR on the experiencing of involved actors in creative processes across fields are rare. We ask how core professional actor groups including creators, legal professionals and managers involved in creative processes experience regulatory uncertainty in the fields of music and pharma. By studying practices of engaging with, circumventing and avoiding regulatory uncertainty about IPR, we show how creative processes in both the music and pharma fields are entrenched with emotional-cognitive experiences such as anxiety, indifference and hope that vary by professional group. Our findings point toward managers and legal professionals observing, exposing and cultivating emotions by ascribing experiences to other actor groups. We conclude that comparing regulation-related emotions of involved actors across fields helps to develop a deeper understanding of the dynamics of creative processes.
In case you or your institution does not have access to RSO please do not hesitate to contact me so I can send you a copy of our article.
governancexborders.com 